A dramatic rise in type 2 diabetes has led to an increase in peripheral neuropathy. New research published in Nature from the lab of Clifford Woolf, led by Sara Hakim, at Boston Children's Hospital ...

Worldwide, cancer chemotherapy is linked to persistent severe peripheral nerve pain (neuropathy) for around 4 in every 10 patients treated with these drugs, suggests a pooled data analysis of the ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).

Introducing Journavx: the FDA-approved non-opioid, non-addictive drug for acute pain. A major breakthrough in pain medication ...

Doctors from the Cleveland Clinic talk about how this new non-opioid pain medication could help reduce the issue of opioid ...

According to published results, a novel opioid-free pathway may provide noninferior pain management compared with an opioid-containing pathway during the perioperative period in patients undergoing ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system, a validated target for peripheral pain management. Because suzetrigine blocks pain signals ...